TipRanks
Advertisement
Advertisement

MBX Stock Latest News

MBX Biosciences Begins Pivotal Phase 3 Canvuparatide Trial
Company AnnouncementsMBX Biosciences Begins Pivotal Phase 3 Canvuparatide Trial
1M ago
8K
MBX
MBX Biosciences doses first patient in oPTimize clinical trial
PremiumThe Fly
MBX Biosciences doses first patient in oPTimize clinical trial
1M ago
MBX
MBX Biosciences reinstated with an Overweight at JPMorgan
PremiumThe Fly
MBX Biosciences reinstated with an Overweight at JPMorgan
1M ago
MBX
MBX Biosciences price target raised to $88 from $70 at Truist
PremiumThe Fly
MBX Biosciences price target raised to $88 from $70 at Truist
2M ago
MBX
MBX Biosciences price target raised to $88 from $70 at Barclays
PremiumThe Fly
MBX Biosciences price target raised to $88 from $70 at Barclays
2M ago
MBX
MBX Biosciences reports Q2 EPS (78c), consensus (59c)
PremiumThe FlyMBX Biosciences reports Q2 EPS (78c), consensus (59c)
2M ago
MBX
MBX Biosciences Advances Canvuparatide and Obesity Pipeline
Premium
Company Announcements
MBX Biosciences Advances Canvuparatide and Obesity Pipeline
2M ago
8K
MBX
MBX Biosciences price target raised to $91 from $57 at Mizuho
Premium
The Fly
MBX Biosciences price target raised to $91 from $57 at Mizuho
2M ago
MBX
MBX Biosciences price target raised to $90 from $60 at UBS
PremiumThe Fly
MBX Biosciences price target raised to $90 from $60 at UBS
2M ago
MBX
MBX: Leadership Transition, Pipeline Visibility Support Maintained Buy Rating and Unchanged $91 Price Target
PremiumRatings
MBX: Leadership Transition, Pipeline Visibility Support Maintained Buy Rating and Unchanged $91 Price Target
3M ago
MBX
Closing Bell Movers: Trex up 6% after positive Q2 pre-announcement
PremiumThe Fly
Closing Bell Movers: Trex up 6% after positive Q2 pre-announcement
3M ago
FBK
LEU
MBX Biosciences Announces CEO Transition and Leadership Updates
PremiumCompany Announcements
MBX Biosciences Announces CEO Transition and Leadership Updates
3M ago
8K
MBX
MBX Biosciences CEO Kent Hawryluk steps down, Steve Hoerter succeeds
PremiumThe FlyMBX Biosciences CEO Kent Hawryluk steps down, Steve Hoerter succeeds
3M ago
MBX
MBX Biosciences Completes STEADI Trial, Putting Imapextide on Investors’ Radar
Premium
Company Announcements
MBX Biosciences Completes STEADI Trial, Putting Imapextide on Investors’ Radar
3M ago
MBX
Analyst Reiterates Buy on MBX, Maintains $91 Price Target on Canvuparade’s Once-Weekly Hypoparathyroidism Opportunity
Premium
Ratings
Analyst Reiterates Buy on MBX, Maintains $91 Price Target on Canvuparade’s Once-Weekly Hypoparathyroidism Opportunity
3M ago
MBX
MBX Biosciences down 19% at $30.05 after announcing canvuparatide study results
PremiumThe Fly
MBX Biosciences down 19% at $30.05 after announcing canvuparatide study results
4M ago
MBX
MBX Biosciences unveils positive Phase 2 canvuparatide results
PremiumCompany Announcements
MBX Biosciences unveils positive Phase 2 canvuparatide results
4M ago
8K
MBX
MBX Biosciences announces results from Avail, canvuparatide trials
PremiumThe Fly
MBX Biosciences announces results from Avail, canvuparatide trials
4M ago
MBX
MBX Biosciences Shareholders Approve Directors and Auditor
PremiumCompany Announcements
MBX Biosciences Shareholders Approve Directors and Auditor
4M ago
8K
MBX
MBX Biosciences price target raised to $56 from $50 at Stifel
PremiumThe FlyMBX Biosciences price target raised to $56 from $50 at Stifel
5M ago
MBX
MBX Biosciences price target raised to $70 from $66 at Barclays
Premium
The Fly
MBX Biosciences price target raised to $70 from $66 at Barclays
5M ago
MBX
MBX Biosciences price target raised to $86 from $76 at Citizens
Premium
The Fly
MBX Biosciences price target raised to $86 from $76 at Citizens
5M ago
MBX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >